Bipolar Disorder

Objective
Cassiopée introduces biomarkers able to differentiate between pathogenic processes (manic, mixed, depressed episode) and the euthymic phase in Bipolar Disorder (BD) with the aim to detect responses to therapeutical intervention(s) of patients using non-disruptive sensory wearables resulting in improved conditions of patients due to prediction of manic states occurrence.

Impacts on Patients’ Quality of Life
We strive to objectively differentiate the phases of bipolar disorder in order to detect therapeutical response or relapse and to identify bipolar disorder subtype(s). The “predictive” adjective is meant to indicate the possibility to monitor fine changes during treatment yielding a personalized approaches to BD. The predictive tool BD application of Cassiopée allows to treat the patient early in the episode(s) resulting in lesser functional impact on patients, and to avoid some side-effects of BD. For more detailed outline of the theory see, e.g., Publications.

Solution
Cassiopée provides diagnose BD with a multi-modal sensory approach providing multi-dimensional time-series that we project on fractal complexity space(s) to track subtle behavioral and physiological changes.

For more infos and use of this diagnostic system, please, contact Cassiopée.

Complexity of Bipolar Disorder

The complexity characterization of BD states using Active-meter x-component of acceleration of a patient suffering from Bipolar Disorder. Data provided by CHUV, Department of Psychiatry, Lausanne, Switzerland.